GLP-1/GIP长效激动剂及MUC-17 ADC齐传捷报 华东医药研发实力再获验证

Core Viewpoint - East China Pharmaceutical's subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., has achieved positive results in the Phase II clinical trial of its innovative dual-target long-acting agonist HDM1005 for weight management, showcasing the company's strong R&D capabilities in metabolic diseases [1][2]. Group 1: HDM1005 Development - HDM1005 is a novel class of chemical drug that acts as a dual-target long-acting agonist for GLP-1 and GIP receptors, with preclinical studies indicating its potential to improve metabolic functions, reduce oxidative stress, and enhance cardiovascular adaptability [1]. - The clinical development of HDM1005 is progressing systematically, with the Phase III trial for weight management expected to complete the first subject enrollment by October 2025, and the Phase II trial for diabetes having completed subject enrollment by July 2025 [2]. - Applications for clinical trials of HDM1005 in multiple indications, including metabolic-associated fatty liver disease (MAFLD) and metabolic-associated fatty liver inflammation (MASH), have been approved in both China and the United States, indicating a comprehensive global clinical development strategy [2]. Group 2: HDM2012 Development - HDM2012, a novel antibody-drug conjugate targeting MUC-17, has received orphan drug designation from the FDA for gastric cancer and pancreatic cancer, highlighting the international recognition of the drug's innovative R&D [2]. - HDM2012 is the first ADC product targeting MUC-17 and is currently the only ADC drug in clinical research for this target, which is highly expressed in gastric, colorectal, and pancreatic cancers but has limited expression in normal organs [2]. - Preclinical results for HDM2012 demonstrate good drug-like properties, safety, and efficacy, with clinical trials in China and the U.S. receiving approval in July and June 2025, respectively, for advanced malignancies [3].